March 26, 2024
Eli Lilly and Nippon Shinyaku said on March 25 that they have signed an alliance agreement in Japan for pirtobrutinib, a non-covalent BTK inhibitor now being developed by the US giant for the treatment of mantle cell lymphoma (MCL) and...read more